Clinical Trials Logo

Hydrocephalus, Normal Pressure clinical trials

View clinical trials related to Hydrocephalus, Normal Pressure.

Filter by:

NCT ID: NCT06129565 Not yet recruiting - Clinical trials for Low Pressure Hydrocephalus

The Use of Q-Collar to Increase CSF Drainage in Low-pressure Hydrocephalus Patients

Start date: November 2023
Phase: N/A
Study type: Interventional

The investigators hypothesize that the Q-collar compression on bilateral internal jugular veins of patients with low pressure hydrocephalus will decrease venous drainage from the intracranial space, therefore increasing intracranial volume, decreasing brain compliance, and increasing CSF drainage through the shunt. This should improve persistent hydrocephalus symptoms and demonstrate improved ventricular drainage on imaging with decompressed ventricles.

NCT ID: NCT06083233 Not yet recruiting - Brain Damage Clinical Trials

Role of Brain Specific Biomarkers in Hydrocephalus

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Normal pressure hydrocephalus (NPH) is a neurodegenerative disease of unclear etiology characterized by a clinical trias named after the neurosurgeon Hakim. It includes cognitive impairment (dementia), gait disturbance, and urinary incontinence. These symptoms, which frequently occur in the elderly population, often overlap with the symptoms of "other" neurodegenerative diseases, especially Alzheimer's disease and other (pre)senile dementias. To distinguishing NPH from "other" dementias is crucial in determining whether a patient will benefit from a surgical procedure (ventriculoperitoneal shunt placement) or not. At the same time, the options for assessing the patient's condition's progression and distinguishing between the progression of neurodegeneration in a broader sense or malfunction of the drainage system are very limited. Therefore, the role of a biomarker that could meet these expectations mentioned above is highly desirable.

NCT ID: NCT05998473 Active, not recruiting - Parkinson Disease Clinical Trials

Characterization of Dynamic Stability in Normal Pressure Hydrocephalus and Parkinson's Disease

HPGAIT
Start date: June 1, 2023
Phase:
Study type: Observational

This study aims to characterize dynamic stability disorders in two conditions mainly affecting the elderly and with similar walking deficits: hydrocephalus at normal pressure and Parkinson's disease, to provide the most relevant monitoring criteria in usual care.

NCT ID: NCT05910944 Recruiting - Hydrocephalus Clinical Trials

European Study of Prodromal iNPH

STOP iNPH
Start date: November 1, 2023
Phase:
Study type: Observational

To investigate if progression from prodromal into symptomatic NPH can be predicted from advanced neuroimaging, biomarkers in cerebrospinal fluid (CSF) and plasma and investigate the unknown mechanisms causing deterioration by investigating longitudinal changes in the above-mentioned variables. Three different cohorts with both asymptomatic and symptomatic patients as well as healthy controls will be investigated over time, both without intervention and before and after shunt surgery.

NCT ID: NCT05679934 Recruiting - Clinical trials for NPH (Normal Pressure Hydrocephalus)

The Effects of Exercise on Gait Characteristics, Balance, and Performance in Patients With Normal Pressure Hydrocephalus

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to investigate effect of exercise program on balance, gait and performance in patients with normal pressure hydrocephalus applied with lumbar puncture. The main question it aims to answer are: - Home based exercise program effective on balance, gait and performance - Telerehabilitation exercise program effective on balance, gait and performance Researchers will compare home based exercise group, telerehabilitation group and control group to see if difference in terms of balance, gait and performance

NCT ID: NCT05562596 Not yet recruiting - Clinical trials for Cognitive Impairment

Normal Pressure Hydrocephalus Biomarkers Investigation

NORPHY
Start date: October 30, 2022
Phase:
Study type: Observational

Normal Pressure Hydrocephalus (NPH) is a clinical condition that induces cognitive deterioration that can be reverted, at least in part, by introducing ventricular-peritoneal diversion controlled by a miniaturized valve system. Mechanisms involved in such an improvement of cognitive function after liquor diversion are unknown. Oxysterols are a family of cholesterol-related compounds having diverse biological functions. Among others, they are involved in cholesterol homeostasis in the brain and are detectable in liquor, potentially impacting neurodegeneration. NPH is an ideal clinical model to study oxysterol distribution in liquor before and after ventricular-peritoneal diversion.

NCT ID: NCT05397106 Recruiting - Brain Tumor Clinical Trials

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Start date: January 24, 2023
Phase:
Study type: Observational

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

NCT ID: NCT05250505 Recruiting - Hydrocephalus Clinical Trials

Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

The eShunt System includes proprietary delivery componentry and the eShunt Implant, a permanent implant deployed in a minimally invasive, neurointerventional procedure. The eShunt Implant is designed to mimic the function of the arachnoid granulations by draining excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

NCT ID: NCT05232838 Recruiting - Hydrocephalus Clinical Trials

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.

NCT ID: NCT05204745 Completed - Dementia Clinical Trials

Ventriculomegaly and Gait Disturbance in the Senior Population in the Region of Västerbotten

VESPR
Start date: February 14, 2018
Phase:
Study type: Observational

Idiopathic normal pressure hydrocephalus (INPH) is a treatable disease of the elderly, typically causing gait impariment, dementia and urinary incontinence. The objective of this study is to make an epidemiological survey of INPH in Umeå, Sweden. Subjects with self-perceived gait impairments will be identified through a questionnaire. They will go through clinical examinations and have an MRI of the brain. A control population will also be investigated to enable comparisons between the populations. The main hypothesis is that the prevalence of INPH in the population is higher than what is previoulsy known.